Physician

Scott A. Tetreault, M.D.

According to 2025 Medicare claims, Scott Tetreault, M.D. (NPI: 1457334914) practices hematology/oncology in the Tallahassee, FL market, with the plurality of this provider's patient population coming from Leon, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 32308-5333.

Tetreault's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 227 traditional Medicare patients, billed 168,064 HCPCS/CPT codes, and received $2,233,953 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 771 prescription claims across 188 beneficiaries totaling $1,696,454 in drug costs, led by Imbruvica (Ibrutinib). 2021 DME data shows 12 claims. Open Payments data shows 100 records totaling $1,998. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $1,730,938 and ending at $2,233,953. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $847,189 and ending at $1,696,454. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	217	111,722	$1,730,938
2016	242	123,496	$1,611,733
2017	291	120,866	$2,077,578
2018	326	215,690	$3,410,559
2019	318	171,483	$2,773,718
2020	362	187,504	$2,936,942
2021	353	208,611	$3,534,618
2022	364	177,912	$2,918,030
2023	319	202,234	$3,863,509
2024	227	168,064	$2,233,953

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	111	573	$847,189
2016	131	703	$1,029,013
2017	129	757	$1,602,097
2018	181	1,238	$1,879,234
2019	175	1,190	$2,302,329
2020	187	955	$1,303,673
2021	189	865	$1,305,750
2022	185	739	$1,596,494
2023	212	900	$1,304,409
2024	188	771	$1,696,454

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	58	$3,882
2016	N/R	44	$802
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	27	$822
2021	N/R	12	$101
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	132	259	$93
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	115	170	$12
36415	Insertion of needle into vein for collection of blood sample	189	698	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	204	1,052	$8
85045	Red blood count, automated test	102	115	$4

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Imbruvica	Ibrutinib	19	546	$309,639
Revlimid	Lenalidomide	14	392	$253,072
Xtandi	Enzalutamide	16	462	$205,799
Eliquis	Apixaban	35	1,621	$31,409
Exemestane	Exemestane	34	2,073	$7,450

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	100	$1,998	Ipsen Biopharmaceuticals, Inc
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Scott A. Tetreault, M.D.?

Tedicare shows public-source Medicare data for Scott A. Tetreault, M.D. (NPI 1457334914), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Scott A. Tetreault, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Scott A. Tetreault, M.D.?

Scott A. Tetreault, M.D. is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Scott A. Tetreault, M.D. have Open Payments data?

Scott A. Tetreault, M.D. has 100 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.